An Introduction to Biotechnology: Recombinant DNA Technology
Biotechnology is the application of biological systems, organisms, or biomolecules to develop technologies and products that improve human life and address societal challenges (Gupta et al. 2016).
What once started as a distant dream for humanity has become reality, with biotechnology creating recombinant DNA (rDNA) technology. Recombinant DNA (rDNA) technology involves combining DNA sequences from different sources to create novel DNA molecules with desired genetic characteristics. These recombinant DNA molecules can then be introduced into living organisms, enabling the production of proteins or traits that would otherwise be difficult or impossible to obtain (Smith 2023). Such technology has not only enabled scientists to manipulate DNA fragments to study them in greater depth, but has also helped produce a diverse array of proteins through microorganisms, which were previously unavailable, expensive, and difficult to obtain (Khan et al. 2016; Fakruddin et al 2012).
rDNA technology enables us to efficiently, safely, and sustainably produce vital proteins required to solve health and dietary problems, and can even be multidisciplinarily applied to combat important issues that we deal with, such as in the field of agriculture, to enhance food resource yield through resistance to adverse environmental conditions (Vipra et al. 2022; Mirsalami & Mirsalami 2025). Additionally, pharmaceuticals produced by rDNA technology have been rapidly implemented in commercial settings, with specialised techniques of rDNA technology having aided the processes of gene therapy and genetic modification, significantly improving the efficacy of bioremediation and the treatment of serious diseases (Khan et al. 2016). Currently, rDNA technology has aided in the production of new vaccines, effective antibiotics, and much more in the pharmaceutical field, which attests to the unique impact that it brings in enhancing the quality of human life (Wetterstrand 2022; LibreTexts 2024).
Modern biotechnological innovations require the efficient and effective domestication of cells to utilize as biological frameworks (Khan et al. 2016). Currently, Escherichia coli (E. coli) serves as one of the most important host and model organisms, or “expression platform,” for rDNA technology— as a host for heterologous protein production, or “the expression of recombinant proteins in cells in which they do not naturally occur—to produce enzymes and therapeutic proteins (Fakruddin et al. 2012; Jester et al. 2022). Escherichia coli (E. coli) is one of the most widely used host organisms for recombinant protein expression (Fakruddin et al. 2012; Jester et al. 2022). Its popularity stems from its rapid growth, low cultivation costs, well-characterised genetics, ease of genetic manipulation, high yield, and compatibility with established molecular biology technology. Furthermore, commonly used laboratory strains, such as K-12 derivatives, are non-pathogenic and safe to handle under standard laboratory conditions (Vendette 2025; Marco 2025).
Since its adoption as a recombinant expression host, E. coli has been used to produce numerous therapeutically important proteins. The first major success was recombinant human insulin, which became the first clinically approved recombinant protein therapeutic and has since improved the lives of millions of people with diabetes worldwide (Fakruddin et al. 2012).
Ultimately, over the years, biotechnology has evolved into a sophisticated discipline and an established field, and has emerged as an integral part of development and innovation, with innovations such as rDNA technology revolutionizing medical research, drug development, and prevention and treatment of diseases, whilst providing major contributions to solving problems in the fields of health, food security, and nature conservation. (Bifulco et al. 2025).
Citations
Bifulco, Maurizio, et al. “The Relevance of the History of Biotechnology for Healthcare.” EMBO Reports, 2 Jan. 2025, https://doi.org/10.1038/s44319-024-00355-8.
Boster. “E. Coli as a Model Organism: Advantages & Limitations | Boster Bio.” Bosterbio.com, 2024, www.bosterbio.com/blog/post/e-coli-as-a-model-organism?srsltid=AfmBOooCCHS4aXUiJmxQg1jYoCpdOUrKhGhk7Nc8AmorZkMqh1pCntfd#limitations. Accessed 26 June 2026.
de Marco, Ario. “Recent Advances in Recombinant Production of Soluble Proteins in E. Coli.” Microbial Cell Factories, vol. 24, no. 1, 16 Jan. 2025, https://doi.org/10.1186/s12934-025-02646-8.
Fakruddin, Md., et al. “Critical Factors Affecting the Success of Cloning, Expression, and Mass Production of Enzymes by Recombinant E. Coli.” ISRN Biotechnology, vol. 2013, no. 1, 2012, pp. 1–7, pmc.ncbi.nlm.nih.gov/articles/PMC4403561/, https://doi.org/10.5402/2013/590587.
Gupta, Varsha, et al. “An Introduction to Biotechnology.” Basic and Applied Aspects of Biotechnology, 23 Oct. 2016, pp. 1–21, www.ncbi.nlm.nih.gov/pmc/articles/PMC7119977/, https://doi.org/10.1007/978-981-10-0875-7_1.
Jester, Benjamin W., et al. “Development of Spirulina for the Manufacture and Oral Delivery of Protein Therapeutics.” Nature Biotechnology, vol. 40, no. 6, 1 June 2022, pp. 956–964, www.nature.com/articles/s41587-022-01249-7, https://doi.org/10.1038/s41587-022-01249-7.
Khan, Suliman, et al. “Role of Recombinant DNA Technology to Improve Life.” International Journal of Genomics, vol. 2016, 8 Dec. 2016, pp. 1–14, pmc.ncbi.nlm.nih.gov/articles/PMC5178364/, https://doi.org/10.1155/2016/2405954.
LibreTexts. “4.3: Applications of Recombinant DNA Technology.” Biology LibreTexts, 10 June 2024, bio.libretexts.org/Courses/West_Los_Angeles_College/Biotechnology/04%3A_Genetic_Engineering_and_Recombinant_DNA_Technology/4.03%3A_Applications_of_Recombinant_DNA_Technology.
Mirsalami, Seyed Mehrdad, and Mahsa Mirsalami. “Advances in Genetically Engineered Microorganisms: Transforming Food Production through Precision Fermentation and Synthetic Biology.” Future Foods, vol. 11, 16 Mar. 2025, p. 100601, www.sciencedirect.com/science/article/pii/S2666833525000644, https://doi.org/10.1016/j.fufo.2025.100601.
Saigo, Mariana, et al. “Biochemical Approaches to C4 Photosynthesis Evolution Studies: The Case of Malic Enzymes Decarboxylases.” Photosynthesis Research, vol. 117, no. 1-3, 7 July 2013, pp. 177–187, https://doi.org/10.1007/s11120-013-9879-1. Accessed 24 Mar. 2021.
Smith, Yolanda. “What Is Recombinant DNA?” News-Medical.net, 16 Aug. 2023, www.news-medical.net/life-sciences/What-is-Recombinant-DNA.aspx.
Vendette, Roger Normand. Why Is E. Coli the Most Widely Used Host in Genetic Engineering, and What Are Its Main Limitations? 21 Aug. 2025, www.researchgate.net/post/Why_is_E_coli_the_most_widely_used_host_in_genetic_engineering_and_what_are_its_main_limitations/68ce063cdd8e695d450af558/citation/download.
Vipra, Madhura, et al. “Applications of Recombinant DNA Technology.” Techniques in Life Science and Biomedicine for the Non-Expert, 2022, pp. 143–157, https://doi.org/10.1007/978-3-030-96851-9_9.
Wetterstrand, Kris. “Recombinant DNA Technology.” National Human Genome Research Institute, 2022, www.genome.gov/genetics-glossary/Recombinant-DNA-Technology.
Comments